MedPath

Atropine

Generic Name
Atropine
Brand Names
Atnaa, Atropen, Busulfex, Donnatal, Duodote, Enlon-plus, Isopto Atropine, Lomotil, Minims Atropine Sulphate, Motofen, Phenohytro
Drug Type
Small Molecule
Chemical Formula
C17H23NO3
CAS Number
51-55-8
Unique Ingredient Identifier
7C0697DR9I
Background

Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active. Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosseous, endotracheal and ophthalmic methods. Oral atropine is only available in combination products. Atropine is a competitive, reversible antagonist of muscarinic receptors that blocks the effects of acetylcholine and other choline esters. It has a variety of therapeutic applications, including pupil dilation and the treatment of anticholinergic poisoning and symptomatic bradycardia in the absence of reversible causes. Atropine is a relatively inexpensive drug and is included in the World Health Organization List of Essential Medicines.

Indication

The intravenous, intramuscular, subcutaneous, intraosseous and endotracheal use of atropine is indicated for the temporary blockade of severe or life-threatening muscarinic effects. The intramuscular use of atropine in the form of a pen injector is indicated for the treatment of poisoning by susceptible organophosphorus nerve agents having cholinesterase activity as well as organophosphorus or carbamate insecticides in adult and pediatric patients. The ophthalmic use of atropine is indicated for mydriasis, cycloplegia, and penalization of the healthy eye in the treatment of amblyopia.

In combination with difenoxin or diphenoxylate (tablets for oral use), atropine is indicated as adjunctive therapy in the management of acute nonspecific diarrhea.

Associated Conditions
Amblyopia, Atrioventricular Heart-block, Bradycardia, Bronchospasm, Crying, Detrusor Hyperreflexia, Excessive bronchial secretion, Hypertonic uterine contraction, Hypertonicity of the small intestine, Ocular Inflammation, Parkinsonism, Peptic Ulcer, Poisoning by parasympathomimetics (cholinergics), Poisoning caused by mushrooms, Poisoning caused by organophosphate anticholinesterase nerve agents, Poisoning caused by organophosphorus pesticides, Pylorospasm, Rhinorrhoea, Sinus Bradycardia, Spasms, Toxic effect of organophosphate and carbamate, Hypermobility of the colon, Laughing, Life-threatening muscarinic side effects, Muscarinic side effects, Severe muscarinic side effects
Clinical Trials
Related News

Pipeline Analysis Reveals 20+ Therapies in Development for Open-Angle Glaucoma Treatment

• DelveInsight's latest report identifies 18+ companies developing 20+ therapeutic candidates for open-angle glaucoma, with several treatments advancing through late-stage clinical trials. • Key players including Nicox, Qlaris Bio, and Glaukos Corporation are making significant progress with innovative treatments like NCX 470, QLS-111, and iDose TREX, demonstrating positive clinical outcomes. • Novel drug delivery mechanisms, including sustained-release implants and encapsulated cell therapies, are emerging as promising approaches to address the challenges of treatment adherence and efficacy in glaucoma management.

ENTOD Pharmaceuticals Receives First Global Approval for 0.05% Atropine Eye Drops to Combat Childhood Myopia

• ENTOD Pharmaceuticals has secured CDSCO approval for Myatro XL (0.05% atropine eye drops), designed to slow myopia progression in children aged 6-12 years, marking the first global regulatory approval for this specific treatment strength. • Phase 3 clinical trial data demonstrated that Myatro XL was more effective than 0.01% atropine in controlling myopia progression, with 76.09% of right eyes showing less than 0.50D progression compared to 65.56% with the lower concentration. • The prescription-only treatment will be available in India starting July 2025, accompanied by a dedicated mobile app to improve patient adherence through reminders and monitoring capabilities.

FDA Expands Luminopia's Digital Therapeutic Approval for Amblyopia Treatment to Children Aged 8-12

• Luminopia's VR-based digital therapeutic for amblyopia has received FDA clearance for children aged 8-12 years, expanding from its previous 4-7 year age indication based on robust real-world evidence. • The treatment offers a novel binocular approach using modified TV content through VR headsets, showing comparable efficacy in pre-teens as in younger children—the first such approval for this age group in over 20 years. • Patients previously treated with traditional therapies for an average of 1.8 years still gained an additional line of vision when switching to Luminopia, addressing a significant unmet need for approximately 400,000 older children with amblyopia.

FDA Accepts NDA for Sydnexis' SYD-101: First Potential Pharmaceutical Treatment for Pediatric Myopia

• The FDA has accepted Sydnexis' New Drug Application for SYD-101, a low-dose atropine eye drop for pediatric myopia management, with a target action date of October 23, 2025. • If approved, SYD-101 would become the first and only FDA-approved pharmaceutical option for treating progressive myopia in children in the United States, addressing a condition expected to affect 50% of the global population by 2025. • The NDA is supported by the landmark STAR study, a 3-year Phase 3 clinical trial that enrolled 852 pediatric patients aged 3-14 years, making it the largest clinical study ever completed for pediatric myopia progression.

China's NMPA Accepts Vyluma's NVK002 Drug Application for Pediatric Myopia

• China's National Medical Products Administration (NMPA) has accepted the drug application for Vyluma's NVK002 to treat myopia progression in children. • NVK002 (low-dose atropine 0.01%) is a preservative-free eye drop administered nightly and developed by Vyluma, licensed to Zhaoke Ophthalmology. • The application is supported by Phase III trials, Mini-CHAMP and China CHAMP, demonstrating significant efficacy, safety, and patient tolerance versus placebo. • NVK002 is now under regulatory review in the United States, the European Union, and China, marking a significant step in its global availability.

FDA Sets PDUFA Date for Lower-Dose Neffy Nasal Spray in Young Pediatric Patients with Anaphylaxis

• The FDA has set a PDUFA target action date of March 6, 2025, for ARS Pharmaceuticals' sNDA for a 1 mg dose of Neffy (epinephrine nasal spray). • This lower dose is intended for pediatric patients weighing 33 to 66 lbs (15 to 30 kg), expanding treatment options for this vulnerable population. • Neffy was initially approved in August 2024 for anaphylaxis in adults and children over 66 lbs, offering a needle-free alternative to epinephrine injections. • Pending approval, Neffy 1 mg could be available in the second quarter of 2025, providing a more accessible and less intimidating treatment option for young children.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy